The Effect of Transauricular Electrical Vagal Nerve Stimulation on Temporal Summation of Pain in Patients With Back Pain

NCT ID: NCT04503889

Last Updated: 2020-08-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-01-23

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The effect of transauricular electrical vagal nerve stimulation (taVNS) will be studied on temporal summation of heat pain (TSP) in 30 patients with chronic low-back pain and in 30 heathy volunteers. Participants will receive either taVNS or sham stimulation before and during TSP induction in a randomized crossover manner. The participants will be unaware regarding the type of intervention.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain Intensity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Outcome Assessors
Participants and outcome assessor will be unaware regarding the type (real or sham) taVNS intervention

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Real taVNS intervention

taVNS will be administered to cymba conchae of both ears using ECO2-TENS device

Group Type EXPERIMENTAL

Transauricular electrical vagal nerve stimulation

Intervention Type DEVICE

transauricular electrical vagal nerve stimulation will be applied to the cymba conchae of both ears using ECO2 TENS device (manufactured by Schwa-Medico GmbH/Germany) with currency intensity of max 10 mA and current frequency 2/100 Hz.

taVNS sham

Intervention Type DEVICE

ECO2 TENS device (manufactured by Schwa-Medico GmbH/Germany)

Sham

aVNS will be administered to lobes of both ears using ECO2-TENS device

Group Type SHAM_COMPARATOR

Transauricular electrical vagal nerve stimulation

Intervention Type DEVICE

transauricular electrical vagal nerve stimulation will be applied to the cymba conchae of both ears using ECO2 TENS device (manufactured by Schwa-Medico GmbH/Germany) with currency intensity of max 10 mA and current frequency 2/100 Hz.

taVNS sham

Intervention Type DEVICE

ECO2 TENS device (manufactured by Schwa-Medico GmbH/Germany)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Transauricular electrical vagal nerve stimulation

transauricular electrical vagal nerve stimulation will be applied to the cymba conchae of both ears using ECO2 TENS device (manufactured by Schwa-Medico GmbH/Germany) with currency intensity of max 10 mA and current frequency 2/100 Hz.

Intervention Type DEVICE

taVNS sham

ECO2 TENS device (manufactured by Schwa-Medico GmbH/Germany)

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with chronic low-back pain
* age 30-60 yrs old
* without heart disease
* low-back pain intensity at least 4 out of 10 points measured using NRS-10
* without cognitive deficits (Mini Mental State Shake \< 23)

Exclusion Criteria

* opioid medication
* more than 1 low-back surgery
* sensory of motor neurological deficits at the level of back pain
* spinal stenosis
* diabetic polyneuropathy
* skin pathology at the site (cymba conchae) of stimulation
Minimum Eligible Age

30 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Medicine Greifswald

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Taras Usichenko, MD, PhD

Role: STUDY_CHAIR

University Medicine of Greifswald

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Medicine of Greifswald

Greifswald, , Germany

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Taras Usichenko, MD. PhD

Role: CONTACT

+49 383486 ext. 5893

David Naegele

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Taras Usichenko, MD, hD

Role: primary

+49383486 ext. 5893

David Naegele

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BB 095/16

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

taVNS Treatment for Fibromyalgia
NCT04777500 NOT_YET_RECRUITING NA
Effects of taVNS on Fibromyalgia Pain
NCT06193317 NOT_YET_RECRUITING NA
Post-stroke Pain taVNS
NCT06456385 COMPLETED NA